These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 7946455)
21. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. Herold M; Schnohr S; Bittrich H J Clin Oncol; 2001 Jul; 19(14):3439. PubMed ID: 11454895 [No Abstract] [Full Text] [Related]
22. Transient neonatal myelosuppression after fetal exposure to maternal chemotherapy. Case report and review of the literature. Udink ten Cate FE; ten Hove CH; Nix WM; de Vries JI; van de Loosdrecht AA; van Elburg RM Neonatology; 2009; 95(1):80-5. PubMed ID: 18787341 [TBL] [Abstract][Full Text] [Related]
23. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
24. Idarubicin in acute leukemia: an effective new therapy for the future. Arlin ZA Semin Oncol; 1989 Feb; 16(1 Suppl 2):35-6. PubMed ID: 2648582 [No Abstract] [Full Text] [Related]
26. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446 [TBL] [Abstract][Full Text] [Related]
27. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296 [TBL] [Abstract][Full Text] [Related]
28. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935 [TBL] [Abstract][Full Text] [Related]
29. Acute myeloblastic leukemia in pregnancy: a case report and review of the literature. Yucebilgin MS; Cagirgan S; Donmez A; Ozkinay E; Akercan F; Mgoyi L; Vural F Eur J Gynaecol Oncol; 2004; 25(1):126-8. PubMed ID: 15053082 [TBL] [Abstract][Full Text] [Related]
30. [Full-term pregnancy in a patient diagnosed with acute leukemia treated with a protocol including VP-16]. Brunet S; Sureda A; Mateu R; Domingo-Albós A Med Clin (Barc); 1993 May; 100(19):757-8. PubMed ID: 8315966 [No Abstract] [Full Text] [Related]
31. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136 [TBL] [Abstract][Full Text] [Related]
32. Reversible foetal cerebral ventriculomegaly and cardiomyopathy under chemotherapy for maternal AML. Baumgärtner AK; Oberhoffer R; Jacobs VR; Ostermayer E; Menzel H; Voigt M; Schneider KT; Pildner von Steinburg S Onkologie; 2009 Feb; 32(1-2):40-3. PubMed ID: 19209018 [TBL] [Abstract][Full Text] [Related]
33. Acute lymphoblastic leukaemia in pregnancy. Molkenboer JF; Vos AH; Schouten HC; Vos MC Neth J Med; 2005 Oct; 63(9):361-3. PubMed ID: 16244384 [TBL] [Abstract][Full Text] [Related]
34. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968 [TBL] [Abstract][Full Text] [Related]
35. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission. Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211 [No Abstract] [Full Text] [Related]
36. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355 [TBL] [Abstract][Full Text] [Related]
37. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617 [TBL] [Abstract][Full Text] [Related]
38. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults]. Hołowiecki J; Krzemień S; Rudzka E; Krawczyk M; Wojnar J; Hołowiecka B; Wacławik A; Wojciechowska M; Kachel L; Cedrych I Acta Haematol Pol; 1994; 25(3):221-30. PubMed ID: 7992594 [TBL] [Abstract][Full Text] [Related]
39. [Management of hematologic malignancies during pregnancy]. Maloisel F; Dreyfus M; Neuhart D; Ritter J; Oberling F J Gynecol Obstet Biol Reprod (Paris); 1996; 25(6):602-7. PubMed ID: 8964958 [TBL] [Abstract][Full Text] [Related]